Christopher Leamon - Aug 31, 2023 Form 4 Insider Report for Fusion Pharmaceuticals Inc. (FUSN)

Role: Chief Scientific Officer
Signature: /s/ Maria Stahl as Attorney-in-Fact for Christopher Leamon
Stock symbol: FUSN
Transactions as of: Aug 31, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/5/2024, 08:54 AM
Previous filing: Jan 9, 2023
Next filing: Jun 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FUSN	Common Stock	Award		+12K			12K	Aug 31, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FUSN	Stock Option (Right to Buy)	Award	$0	+106K		$0.00	106K	Jan 4, 2024	Common Stock	106K	$8.44	Direct	F2
transaction	FUSN	Restricted Stock Units	Award	$0	+63.7K		$0.00	63.7K	Jan 4, 2024	Common Stock	63.7K		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan.
F2	This option vests in 48 equal monthly installments beginning on February 4, 2024.
F3	Each restricted stock unit represents a contingent right to receive one share of common stock of Fusion Pharmaceuticals Inc. for no consideration.
F4	The restricted stock units vest in six equal installments on each of July 4, 2024, January 4, 2025, July 4, 2025, January 4, 2026, July 4, 2026 and January 4, 2027.